Indian Journal Of Clinical Practice 2024-06-28T09:21:23+00:00 Tanuja Bisht Open Journal Systems <div class="row"> <div class="col-md-12"> <p>Indian Journal of Clinical Practice is the flagship peer-reviewed journal of IJCP Group<br />A multispecialty journal, it provides clinicians with evidence-based updated information about a diverse range of common medical topics, including those frequently encountered by the Indian physician, to make informed clinical decisions.<br /><br />Indian Journal of Clinical Practice is a peer-reviewed journal that publishes original research, clinical reviews, case reports, expert viewpoints, clinical practice guidelines, Medilaw, Medifinance, Spiritual Update, Lighter reading including latest news and updates in medicine from around the globe.<br /><br />Indian Journal of Clinical Practice has been published regularly every month since it was first launched in June 1990 as a monthly medical journal.<br /><br />The journal is available in print and is also available online. The ISSN (print version) number is 0971-0876; RNI number is 50798/1990.<br /><br />Indian Journal of Clinical Practice is indexed with Indian Citation Index and IndMed (</p> <p>IJCP Group was founded in 1990 by Padma Shri and Dr BC Roy National Awardee Dr KK Aggarwal and was the pioneer of medical journalism in India. It was started with the basic objective of updating the knowledge of the medical professionals, which is the need of the hour. We began with a single monthly journal called ‘The Indian Journal of Clinical Practice’ launched in 1990 by Late Dr Shankar Dayal Sharma, the then Vice President of India. Since then we have now grown into various multispecialty journals, customized books and publications, events, consulting, branding, Continuing Medical Education (CME) activities, doctor meetings, Key Opinion Leader (KOL) interactions, etc.</p> </div> </div> <div class="row"> <div class="col-md-12"><strong><span id="ctl00_ContentPlaceHolder1_Label2">Aim &amp; Mission</span></strong></div> </div> <div class="row"> <div class="col-md-12"> <p><br /><strong>Our Aim</strong><br />To help medical professionals both within India and abroad to stay updated with the latest advances in medicine and help improve patient outcomes and to provide a platform for doctors to share information<br /><br /><strong>Our Mission</strong><br />To be the leader in the field of medical communications and to make Indian medical literature vastly read within India and abroad.<br /><br /><strong>Our Vision</strong><br />To benchmark the kaleidoscope of medical information<br /><br /><strong>Our Guiding Principles</strong><br />Content is King, commitment, excellence, quality, timeline efficiency, creativity, innovation</p> </div> </div> Medicine Update 2024-06-28T05:18:44+00:00 Dr Veena Aggarwal <p>EDITORIAL</p> 2024-06-28T00:00:00+00:00 Copyright (c) 2024 Indian Journal Of Clinical Practice Silver Stewardship 2024-06-28T05:24:05+00:00 Dr Sanjay Kalra Dr Navneet Agrawal Dr Nitin Kapoor <p>GUEST EDITORIAL</p> 2024-06-28T00:00:00+00:00 Copyright (c) 2024 Indian Journal Of Clinical Practice Birth Defects with the Use of Valproate: An Impact on the Prescribing Pattern amongst the Health Care Professionals in India 2024-06-28T05:31:49+00:00 Dr V KALAISELVAN Dr NISHITH KESERWANI Dr RISHI KUMAR Dr RAJEEV SINGH RAGHUVANSHI Dr KRISHNAMURTHY B <p>Objective: The present study was carried out to evaluate the impact of Pharmacovigilance Programme of India (PvPI) initiative <br>to reduce the use of sodium valproate/valproic acid (SV/VA) in the women of childbearing age group. Methods: In our <br>questionnaire-based study, 251 health care professionals (HCPs) participated from 41 medical colleges across India, which are <br>also working as Adverse drug reaction Monitoring Centres (AMCs) under PvPI. Results: The data collected at the National <br>Coordination Centre (NCC) shows the significant decrease in the use of SV/VA in the women of childbearing age group after <br>the PvPI initiative on Information, Education, and Communication (IEC) materials for HCPs. However, it was found that <br>40% of HCPs of Gynecology and Neurology Department were still not aware of the initiative taken by the Government of <br>India to reduce the use of SV/VA in the women of childbearing age group. Conclusion: PvPI, therefore, needs to take more <br>measures to increase the reach of their resource materials to all HCPs.</p> 2024-06-28T00:00:00+00:00 Copyright (c) 2024 Indian Journal Of Clinical Practice Role of Beta-Blockers in Prevention of Hepatopulmonary Syndrome in Chronic Liver Disease: An Observation 2024-06-28T06:25:58+00:00 Dr ASHISH GAUTAM Dr PRABHAT AGRAWAL Dr ASHWINI NIGAM <p>Aim: Study was initiated to study the presence of hepatopulmonary syndrome (HPS) in chronic liver disease patients, and role <br>of beta-blockers in its occurrence. Methods: Patients admitted in Dept. of Medicine and patients attending the Medicine OPD <br>were examined and investigated for presence of HPS irrespective of its typical clinical features as explained in the literature. <br>Patients having ascites or pleural effusion were managed by means of paracentesis and pleural tap first and then included <br>in the study. Patients having any other primary pulmonary disease like bronchial asthma or chronic obstructive pulmonary <br>disease were excluded from the study. Arterial blood gas analysis and contrast-enhanced echocardiography was done to confirm <br>presence of arterial hypoxemia and pulmonary shunt, the diagnostic criteria. Results: During 1 year study, total 125 patients <br>were enrolled in the study after appropriate selection criteria. Twenty-eight out of 125 patients were not taking propranolol. <br>Propranolol is contraindicated in these patients for one or two reasons. Four out of these 28 patients developed HPS. One out <br>of 97 patients who were on propranolol developed HPS. Total 5 patients were confirmed having HPS. The Fisher’s exact test <br>statistic value is 0.008887. The result is significant at p &lt; 0.01. Conclusion: Patients of cirrhosis with portal hypertension on <br>treatment with propranolol were having significantly lower chances of development of HPS then those without propranolol. <br>Propranolol may have preventive role for development of HPS.</p> 2024-06-28T00:00:00+00:00 Copyright (c) 2024 Indian Journal Of Clinical Practice Hepatic Granulomas: A Clinician’s Perspective 2024-06-28T06:07:51+00:00 Dr MAYANK JAIN Dr JOY VARGHESE Dr JAYANTHI VENKATARAMAN <p>Hepatic granulomas are focal aggregates of transformed epithelioid histiocytes with or without multinucleated giant cells that are <br>cuffed by lymphocytes and plasma cells. They represent delayed-type specialized cell-mediated immunity to a wide-spectrum <br>of antigenic stimuli. Hepatic granulomas are found in up to 10% of liver biopsies and the causes are usually multifactorial. <br>Different antigens like infectious agent, medication, foreign body and malignancy can initiate granuloma formation. Hepatic <br>granulomas per se seldom cause architectural changes and often provide a clue to a systemic disease. Most often, to a practicing <br>clinician, it is a combination of clinical presentation, laboratory parameters with information on the typical localization and <br>characterization of the granuloma within the liver by the pathologist that often provides a clue to a definitive diagnosis.</p> 2024-06-28T00:00:00+00:00 Copyright (c) 2024 Indian Journal Of Clinical Practice A Rare Convergence: A Case Report on Bilateral Hypoglossal Schwannoma in a Patient with Charcot-Marie-Tooth Disease 2 2024-06-28T06:32:50+00:00 Dr K SANKAVI GAUTHAM Dr CJ SELVAKUMAR Dr V SADEESH KUMAR† Dr M SACRATIS Dr N SHOBANA <p>This case presents a rare co-occurrence of Charcot-Marie-Tooth disease type 2 (CMT2) and schwannoma, shedding light on <br>the intricate relationship between two neurogenic disorders. CMT is a hereditary sensorimotor peripheral neuropathy while <br>schwannoma is a benign encapsulated tumor involving Schwann cells. The co-occurrence has been previously described in <br>2 patients in a family with CMT type 1A. Our case reports the first documented instance of the co-occurrence of bilateral <br>hypoglossal schwannoma in CMT2.</p> 2024-06-28T00:00:00+00:00 Copyright (c) 2024 Indian Journal Of Clinical Practice Unveiling the Nexus of Cognitive Impairment in Diabetes: Exploring the Enigmatic “Diabetic Melancholy” 2024-06-28T06:45:17+00:00 Dr RITWIK GHOSH Dr SUBHANKAR CHATTERJEE Dr RANA BHATTACHARJEE Dr Souvik Dubey <p>Patients living with diabetes suffer from a spectrum of cognitive and mood disorders. To encompass the diverse <br>neuropsychological aspects of diabetes, the authors herein propose the new construct of “diabetic melancholy”, which <br>stands for memory impairments, executive dysfunctions, language impairments, psychomotor retardation, low mood, and <br>apathy. Authors have also described the underlying neural basis of cognitive dysfunction in diabetes.</p> 2024-06-28T00:00:00+00:00 Copyright (c) 2024 Indian Journal Of Clinical Practice Patient Care and Medical Decision-Making 2024-06-28T06:57:34+00:00 IJCP <p>MEDICOLEGAL</p> 2024-06-28T00:00:00+00:00 Copyright (c) 2024 Indian Journal Of Clinical Practice 64th Annual Conference of the Indian Society of Gastroenterology (ISGCON 2023) 2024-06-28T07:02:38+00:00 IJCP <p>CONFERENCE PROCEEDINGS</p> 2024-06-28T00:00:00+00:00 Copyright (c) 2024 Indian Journal Of Clinical Practice News and Views 2024-06-28T07:06:52+00:00 IJCP <p>AROUND THE GLOBE</p> 2024-06-28T00:00:00+00:00 Copyright (c) 2024 Indian Journal Of Clinical Practice The Lips of Truth shall be Recognized Forever, a Lying Tongue is but for a Moment 2024-06-28T07:11:16+00:00 IJCP <p>SPIRITUAL UPDATE</p> 2024-06-28T00:00:00+00:00 Copyright (c) 2024 Indian Journal Of Clinical Practice How do we Affect Others 2024-06-28T07:13:34+00:00 IJCP <p>INSPIRATIONAL STORY</p> 2024-06-28T00:00:00+00:00 Copyright (c) 2024 Indian Journal Of Clinical Practice Lighter Side of Medicine 2024-06-28T07:17:27+00:00 IJCP <p>LIGHTER READING</p> 2024-06-28T00:00:00+00:00 Copyright (c) 2024 Indian Journal Of Clinical Practice From Evidence to Practice: Denosumab in Osteoporosis and Joint Health 2024-06-28T09:21:23+00:00 Dr SANJAY AGARWALA Dr DHANANJAY GUPTA Dr SANJAY YADAV Dr VIJAY GONI Dr ANIL MEHTANI Dr KAMAL BACHANI Dr SUBHASH JANGID Dr SUDHIR SETH Dr NIRAD VEGSARKAR Dr SHUBHRANSHU SHEKHAR MOHANTY Dr PRADEEP BHOSALE Dr HEMANT BHANDARI <p>Osteoporosis and osteopenia are prevalent conditions in India, particularly among postmenopausal women and the elderly, <br>leading to increased fracture risks and morbidity. Denosumab, a monoclonal antibody, demonstrates superior efficacy <br>over other treatments in reducing fracture risk and enhancing bone mineral density (BMD). Clinical trials highlight its <br>effectiveness in preventing periprosthetic bone loss, improving implant stability, and mitigating femoral head collapse in <br>various conditions; combination therapies involving denosumab further amplify BMD gains and reduce fracture risk. The <br>article reviews the efficacy and safety of denosumab in managing osteoporosis, joint replacement therapy, and avascular <br>necrosis based on a review of clinical evidence and studies. Denosumab emerges as a cornerstone therapy for osteoporosis <br>management, offering multifaceted benefits in fracture prevention, joint replacement therapy, and avascular necrosis.</p> 2024-06-28T00:00:00+00:00 Copyright (c) 2024 Indian Journal Of Clinical Practice